Berndt Modig Sells 2,291 Shares of Pharvaris (NASDAQ:PHVS) Stock

Pharvaris N.V. (NASDAQ:PHVS) CEO Berndt Modig sold 2,291 shares of the business’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $31.07, for a total value of $71,181.37. Following the completion of the transaction, the chief executive officer owned 135,209 shares in the company, valued at $4,200,943.63. This trade represents a 1.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Berndt Modig also recently made the following trade(s):

• On Monday, May 18th, Berndt Modig sold 2,292 shares of Pharvaris stock. The shares were sold at an average price of $29.22, for a total value of $66,972.24.
• On Thursday, April 16th, Berndt Modig sold 2,292 shares of Pharvaris stock. The shares were sold at an average price of $28.60, for a total value of $65,551.20.
• On Thursday, April 9th, Berndt Modig sold 23,333 shares of Pharvaris stock. The shares were sold at an average price of $27.74, for a total value of $647,257.42.

Pharvaris Stock Up 6.2%

PHVS stock traded up $1.95 during trading on Wednesday, hitting $33.41. The company had a trading volume of 287,421 shares, compared to its average volume of 243,226. The firm has a market cap of $2.19 billion, a PE ratio of -10.51 and a beta of -2.35. Pharvaris N.V. has a 1-year low of $16.00 and a 1-year high of $33.50. The firm has a 50-day moving average price of $29.71 and a 200-day moving average price of $27.63.

Pharvaris (NASDAQ:PHVS) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.82) by $0.12. Sell-side analysts anticipate that Pharvaris N.V. will post -3.22 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. GF Fund Management CO. LTD. purchased a new position in shares of Pharvaris in the 4th quarter worth $35,000. JPMorgan Chase & Co. raised its position in Pharvaris by 30.6% in the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after purchasing an additional 783 shares during the period. China Universal Asset Management Co. Ltd. purchased a new position in Pharvaris in the third quarter valued at about $75,000. Barclays PLC purchased a new position in Pharvaris in the fourth quarter valued at about $77,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in Pharvaris in the fourth quarter valued at about $86,000.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. UBS Group set a $74.00 target price on Pharvaris in a report on Wednesday, May 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Pharvaris in a report on Tuesday, April 21st. Wall Street Zen upgraded Pharvaris from a “sell” rating to a “hold” rating in a report on Saturday, June 6th. Citizens Jmp lowered their price target on Pharvaris from $75.00 to $74.00 and set a “market outperform” rating on the stock in a report on Wednesday, May 13th. Finally, Wolfe Research initiated coverage on Pharvaris in a report on Thursday, April 9th. They set an “outperform” rating and a $42.00 target price on the stock. Ten equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $49.18.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.